Skip to content
value.today
Fate Therapeutics, Inc. logo

Fate Therapeutics, Inc.

FATE
$264 Mmarket cap on Oct 29, 2026-30.4% since Jan 2024
Compare
World rank
#15,278
Revenue
$7 M
For year ending December-2025
Net income
$-136 M
-2049.9% margin
SEC filing
Employees
449
As on 2021
value.today research

Fate Therapeutics, Inc. in brief

Fate Therapeutics, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. It was founded in 2007. Its market value was $264 M on 29 October 2026, which makes it the 15,278th largest listed company in the world and the 2,976th largest in the USA on this site. In the year to December 2025 it had sales of $7 M and a net loss of $136 M. It employs about 449 people and Bahram Valamehr is its chief executive. Its shares trade under the symbol FATE (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Fate Therapeutics, Inc.

Fate Therapeutics is a Clinical Stage Biopharmaceutical company. The company is dedicated to the development of next generation cellular immunotherapies for cancer and immune disorders. The headquarters is in USA.

Fate Therapeutics, Inc. timeline

4 events, 2007–2022
  1. 2007
  2. 🏁
    · approximate
    Founded
  3. 2008
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2013
  6. 🔔
    · approximate
    Initial public offering on Nasdaq
  7. 2022
  8. 💰
    Record revenue of $96 million
    FY2022, the highest of the 8 years on record.

Events of Fate Therapeutics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Fate Therapeutics, Inc.

Layoffs
It is planning to cut off 50% of employees i.e 315 employees and announcement made in Jan-2023.

Market cap history

$0 M$2.2 B$4.4 B$6.6 B$8.8 B2020202120222023202420252026

World rank over time

▼ down 9,164 places since 2020
2020-01-01: #6153#6,15320202021-01-01: #1981#1,98120212022-01-07: #3499#3,49920222022-12-25: #8052#8,05220222023-07-30: #13931#13,93120232024-01-05: #14335#14,33520242026-03-08: #9352#9,35220262026-08-01: #14190#14,19020262026-10-08: #15396#15,39620262026-10-29: #15317#15,3172026

Rank in USA: #1,782 (Jan 2020) · #697 (Jan 2021) · #1,166 (Jan 2022) · #1,967 (Dec 2022) · #2,858 (Jul 2023) · #2,758 (Jan 2024) · #1,807 (Mar 2026) · #2,869 (Aug 2026) · #2,978 (Oct 2026) · #2,980 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
39.7×
Price / book
1.3×
Free cash flow yield
-42.5%
Net margin
-2049.9%
Operating margin
-2221.1%
Return on equity
-65.8%
Liabilities / assets
35.0%
Net debt
$-172M
Revenue growth
-51.2%
R&D / revenue
1621.5%
Revenue per employee
$15 K
Profit per employee
$-304 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $5M, net income $-67M$5MFY18Fiscal year ending Dec 2019: revenue $11M, net income $-98M$11MFY19Fiscal year ending Dec 2020: revenue $31M, net income $-173M$31MFY20Fiscal year ending Dec 2021: revenue $56M, net income $-212M$56MFY21Fiscal year ending Dec 2022: revenue $96M, net income $-282M$96MFY22Fiscal year ending Dec 2023: revenue $64M, net income $-161M$64MFY23Fiscal year ending Dec 2024: revenue $14M, net income $-186M$14MFY24Fiscal year ending Dec 2025: revenue $7M, net income $-136M$7MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$7M-51.2%$-148M$-136M-2049.9%
Dec 2024$14M-78.5%$-210M$-186M-1366.5%
Dec 2023$64M-34.0%$-191M$-161M-253.3%
Dec 2022$96M+72.4%$-308M$-282M-292.5%
Dec 2021$56M+77.7%$-217M$-212M-379.9%
Dec 2020$31M+194.3%$-128M$-173M-551.7%
Dec 2019$11M+125.3%$-101M$-98M-919.0%
Dec 2018$5M—$-67M$-67M-1405.1%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-106M$6M$-112M$-1.15—
Dec 2024$-123M$1M$-124M$-1.64—
Dec 2023$-132M$6M$-138M$-1.64—
Dec 2022$-248M$36M$-284M$-2.91—
Dec 2021$-163M$51M$-214M$-2.24—
Dec 2020$-39M$5M$-44M$-2.10—
Dec 2019$-83M$7M$-91M$-1.44—
Dec 2018$-39M$2M$-41M$-1.19—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $2M, net income $-52M$2MDec ’24Three months to Mar 2025: revenue $2M, net income $-38M$2MMar ’25Three months to Jun 2025: revenue $2M, net income $-34M$2MJun ’25Three months to Sep 2025: revenue $2M, net income $-32M$2MSep ’25Three months to Dec 2025 (from the annual report): revenue $1M, net income $-32M$1MDec ’25Three months to Mar 2026: revenue $1M, net income $-31M$1MMar ’26Three months to Jun 2026: revenue $2M, net income $-30M$2MJun ’26Three months to Sep 2026: revenue —, net income $-31M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-31M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Fate Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$7 M
Operating income
$-148 M
Net income
$-136 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$319 M
Total liabilities
$112 M
Total equity
$207 M

As of December-2025

FATE THERAPEUTICS - Annual Results Summary - in Million USD

Year Ending:Total RevenueOperating IncomeNet Income
Dec-202296-308 (Loss)-281 (Loss)
Dec-202155 -216 (Loss)-212 (Loss)
Dec-202031.4(128.1) (Loss)(173.4) (Loss)
Dec-201910.7(100.7) (Loss)(98.1) (Loss)
Dec-20184.7(67.1) (Loss)(66.6) (Loss)
Dec-20174.1(42.1) (Loss)(43.0) (Loss)

Balance sheet

Total Assets as on Dec-2022 was 705 Million USD.

Total Liabilities as on Dec-2022 was 221 Million USD.

Total Equity as on Dec-2022 was 483 Million USD

Top 100 institutional investors in Fate Therapeutics, Inc.#

As of Sep 30, 2026
142 institutions held 71.3 M shares (about 58.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 39.8%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Fate Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Redmile Group, LLC12,872,9460 (0.00%)10.59%$31 MNov 16, 2026
2BlackRock, Inc.7,105,172-193,723 (-2.65%)5.84%$17 MNov 13, 2026
3Vanguard Portfolio Management LLC4,959,037+413,144 (+9.09%)4.08%$12 MNov 13, 2026
4Acadian Asset Management LLC4,765,677+414,427 (+9.52%)3.92%$11 MNov 9, 2026
5Vanguard Capital Management LLC4,496,086+50,550 (+1.14%)3.70%$11 MNov 13, 2026
6Two Sigma Investments, LP3,905,357+315,494 (+8.79%)3.21%$9 MNov 16, 2026
7Johnson & Johnson3,379,0640 (0.00%)2.78%$8 MOct 26, 2026
8Renaissance Technologies LLC2,374,394-608,874 (-20.41%)1.95%$6 MNov 12, 2026
9Arrowstreet Capital, Limited Partnership2,374,346+2,344,170 (+7768.33%)1.95%$6 MNov 13, 2026
10Millennium Management LLC2,167,548-266,430 (-10.95%)1.78%$5 MNov 16, 2026
11Goldman Sachs Group Inc2,061,740+12,553 (+0.61%)1.70%$5 MNov 16, 2026
12Qube Research & Technologies Ltd1,664,316+1,086,166 (+187.87%)1.37%$4 MNov 13, 2026
13Susquehanna International Group, LLP1,563,709+1,052,659 (+205.98%)1.29%$4 MNov 16, 2026
14Geode Capital Management, LLC1,320,456-1,557 (-0.12%)1.09%$3 MNov 6, 2026
15Assenagon Asset Management S.A.1,311,765+1,020,089 (+349.73%)1.08%$3 MOct 15, 2026
16Bruce & Co., Inc.989,1880 (0.00%)0.81%$2 MNov 16, 2026
17Citadel Advisors LLC846,920-146,388 (-14.74%)0.70%$2 MNov 16, 2026
18Connor, Clark & Lunn Investment Management Ltd.735,386+160,391 (+27.89%)0.60%$2 MNov 10, 2026
19Morgan Stanley710,956+16,376 (+2.36%)0.58%$2 MNov 13, 2026
20T. Rowe Price Investment Management, Inc.690,400-389,920 (-36.09%)0.57%$2 MNov 16, 2026
21Charles Schwab Investment Management Inc654,963+44,014 (+7.20%)0.54%$2 MNov 16, 2026
22Vanguard Fiduciary Trust Co640,4280 (0.00%)0.53%$2 MNov 13, 2026
23State Street Corp602,128+43,200 (+7.73%)0.50%$1 MNov 12, 2026
24Dimensional Fund Advisors LP517,313+165,087 (+46.87%)0.43%$1 MNov 4, 2026
25DAFNA Capital Management LLC500,000-25,000 (-4.76%)0.41%$1 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Fate Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Marshall Wace, LLP416,938-75,488 (-15.33%)0.34%$1 MNov 13, 2026
27Privium Fund Management B.V.414,3110 (0.00%)0.34%$1 MNov 3, 2026
28Wellington Management Group LLP410,457+164,643 (+66.98%)0.34%$1 MNov 16, 2026
29Man Group plc368,205+192,098 (+109.08%)0.30%$1 MNov 16, 2026
30AQR Capital Management LLC352,086-3,485,143 (-90.82%)0.29%$1 MNov 16, 2026
31Susquehanna Portfolio Strategies, LLC300,120-37,938 (-11.22%)0.25%$1 MNov 16, 2026
32Invesco Ltd.294,342+28,360 (+10.66%)0.24%$1 MNov 12, 2026
33Cerity Partners LLC288,554-53,178 (-15.56%)0.24%$1 MNov 13, 2026
34Northern Trust Corp243,766+1,095 (+0.45%)0.20%$1 MNov 16, 2026
35Schonfeld Strategic Advisors LLC231,659+165,501 (+250.16%)0.19%$1 MNov 16, 2026
36Point72 Asset Management, L.P.209,501-232,727 (-52.63%)0.17%$0 MNov 16, 2026
37Bridgeway Capital Management, LLC181,900-3,100 (-1.68%)0.15%$0 MNov 16, 2026
38Empowered Funds, LLC181,900New0.15%$0 MNov 13, 2026
39LPL Financial LLC172,746-31,000 (-15.22%)0.14%$0 MNov 6, 2026
40UBS Group AG171,454-418,724 (-70.95%)0.14%$0 MNov 10, 2026
41Bank Of America Corp /de/163,509+9,803 (+6.38%)0.13%$0 MNov 16, 2026
42HSBC Holdings PLC162,802-77,922 (-32.37%)0.13%$0 MNov 16, 2026
43Woodline Partners LP159,6500 (0.00%)0.13%$0 MNov 16, 2026
44Barclays PLC155,215-32,774 (-17.43%)0.13%$0 MNov 6, 2026
45American Century Companies Inc153,722+74,803 (+94.78%)0.13%$0 MNov 12, 2026
46Squarepoint Ops LLC152,247-1,377 (-0.90%)0.13%$0 MNov 9, 2026
47Arete Wealth Advisors, LLC150,0000 (0.00%)0.12%$0 MNov 9, 2026
48Jacobs Levy Equity Management, Inc132,049New0.11%$0 MNov 16, 2026
49Catalyst Funds Management Pty Ltd127,364New0.10%$0 MNov 12, 2026
50Russell Investments Group, Ltd.126,492+20,690 (+19.56%)0.10%$0 MNov 6, 2026
51Panagora Asset Management Inc125,954New0.10%$0 MNov 12, 2026
52National Philanthropic Trust125,0000 (0.00%)0.10%$0 MNov 13, 2026
53Jump Financial, LLC124,047New0.10%$0 MNov 13, 2026
54Gsa Capital Partners LLP119,781+7,514 (+6.69%)0.10%$0 MNov 16, 2026
55XTX Topco Ltd108,180-72,646 (-40.17%)0.09%$0 MNov 16, 2026
56Schulhoff & Co Inc100,0000 (0.00%)0.08%$0 MNov 13, 2026
57Jefferies Financial Group Inc.95,600+36,478 (+61.70%)0.08%$0 MNov 5, 2026
58BNP Paribas Financial Markets75,705-195,929 (-72.13%)0.06%$0 MNov 12, 2026
59ExodusPoint Capital Management, LP71,859New0.06%$0 MNov 16, 2026
60SEI Investments Co70,9800 (0.00%)0.06%$0 MNov 10, 2026
61Corient Private Wealth LP67,024+509 (+0.77%)0.06%$0 MNov 16, 2026
62Graham Capital Management, L.P.65,360+51,211 (+361.94%)0.05%$0 MNov 16, 2026
63Wells Fargo & Company/mn60,115-3,531 (-5.55%)0.05%$0 MNov 16, 2026
64EntryPoint Capital, LLC56,543New0.05%$0 MNov 13, 2026
65Vanguard Personalized Indexing Management, LLC52,306+1,890 (+3.75%)0.04%$0 MNov 16, 2026
66Ieq Capital, LLC49,330-438,398 (-89.89%)0.04%$0 MNov 10, 2026
67Hudson Bay Capital Management LP47,500+22,340 (+88.79%)0.04%$0 MNov 13, 2026
68FMR LLC46,857-2,219 (-4.52%)0.04%$0 MNov 10, 2026
69Y-Intercept (Hong Kong) Ltd45,573+800 (+1.79%)0.04%$0 MOct 16, 2026
70Vanguard Global Advisers, LLC43,754-47,957 (-52.29%)0.04%$0 MNov 13, 2026
71Aster Capital Management (DIFC) Ltd42,584-134,016 (-75.89%)0.04%$0 MNov 12, 2026
72Spark Investment Management LLC42,000New0.03%$0 MNov 13, 2026
73WINTON GROUP Ltd40,400New0.03%$0 MNov 12, 2026
74Abel Hall, LLC35,850-22 (-0.06%)0.03%$0 MOct 19, 2026
75Brevan Howard Capital Management LP33,489New0.03%$0 MNov 16, 2026
76HighTower Advisors, LLC32,000-1,454 (-4.35%)0.03%$0 MNov 10, 2026
77Quantinno Capital Management LP28,930New0.02%$0 MNov 13, 2026
78Focus Partners Wealth28,587-30,960 (-51.99%)0.02%$0 MNov 12, 2026
79FPC Investment Advisory, Inc.26,4560 (0.00%)0.02%$0 MNov 12, 2026
80Citigroup Inc25,199+5,569 (+28.37%)0.02%$0 MNov 4, 2026
81Captrust Financial Advisors23,317-50,295 (-68.32%)0.02%$0 MNov 12, 2026
82Twinbeech Capital LP22,980New0.02%$0 MNov 16, 2026
83Creative Planning22,699-86,281 (-79.17%)0.02%$0 MNov 2, 2026
84Theory Financial LLC22,2220 (0.00%)0.02%$0 MNov 9, 2026
85Bronte Capital Management Pty Ltd.21,7400 (0.00%)0.02%$0 MNov 12, 2026
86Axq Capital, LP20,479-20,377 (-49.88%)0.02%$0 MNov 12, 2026
87Moneta Group Investment Advisors LLC20,245New0.02%$0 MNov 13, 2026
88SummitTX Capital, L.P.18,803New0.02%$0 MNov 16, 2026
89Parametrica Management Ltd18,4720 (0.00%)0.02%$0 MOct 27, 2026
90Tiaa-Cref Individual & Institutional Services, LLC17,5920 (0.00%)0.01%$0 MNov 12, 2026
91Ameritas Advisory Services, LLC16,0000 (0.00%)0.01%$0 MNov 12, 2026
92Aigen Investment Management, LP15,268New0.01%$0 MNov 16, 2026
93Deutsche Bank AG\15,1580 (0.00%)0.01%$0 MNov 6, 2026
94Jane Street Group, LLC14,526-1,012,481 (-98.59%)0.01%$0 MNov 12, 2026
95Neuberger Berman Group LLC13,688-3,008 (-18.02%)0.01%$0 MNov 13, 2026
96Wealth Enhancement Advisory Services, LLC13,447-77,034 (-85.14%)0.01%$0 MOct 13, 2026
97R Squared Ltd13,259+137 (+1.04%)0.01%$0 MNov 6, 2026
98Susquehanna Fundamental Investments, LLC13,0630 (0.00%)0.01%$0 MNov 16, 2026
99Victory Capital Management Inc13,039+261 (+2.04%)0.01%$0 MNov 10, 2026
100Narwhal Capital Management12,7000 (0.00%)0.01%$0 MNov 4, 2026

All 142 institutional investors, with who bought and sold →

Mutual funds holding Fate Therapeutics, Inc.#

62 funds hold shares worth $42 M (about 12.7% of the company). Since their previous reports 28 added shares and 66 sold, selling $2 M net.
Mutual funds holding Fate Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.3.19 M$9 M2.6%<0.01%+7.4%Jun 30, 2026
🇺🇸 Vanguard Strategic Equity FundThe Vanguard Group, Inc.2.96 M$8 M2.4%0.07%+17%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.15 M$3 M0.95%<0.01%+4.1%Jun 30, 2026
🇺🇸 Bruce FundBruce and Company Inc989,188$3 M0.81%0.71%+25%Jun 30, 2026
🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC876,106$2 M0.72%0.05%−1.2%May 29, 2026
🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc.786,810$2 M0.65%0.07%+116%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc.629,759$2 M0.52%0.02%newJun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.559,342$2 M0.46%<0.01%+4.2%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC535,817$2 M0.44%<0.01%+19%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.507,444$1 M0.42%<0.01%−1.6%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors378,180$1 M0.31%0.07%+41%Jun 30, 2026
🇺🇸 Vanguard Market Neutral FundThe Vanguard Group, Inc.308,409$1 M0.25%0.14%no changeJun 30, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.292,658$1 M0.24%<0.01%−0.8%May 31, 2026
🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC256,360$1 M0.21%0.18%+31%Jun 30, 2026
🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds233,942$1 M0.19%0.08%+68%Jun 30, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC228,044$1 M0.19%0.02%−24%Jul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC192,817$1 M0.16%<0.01%+17%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC185,000$0 M0.15%0.34%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC151,779$0 M0.12%<0.01%+7.6%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC93,995$0 M0.08%<0.01%−17%May 31, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.83,030$0 M0.07%0.02%+6.4%May 31, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors85,542$0 M0.07%<0.01%+47%Jun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.74,845$0 M0.06%<0.01%+144%Jun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP70,190$0 M0.06%<0.01%+182%Jul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.51,829$0 M0.04%<0.01%−19%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.50,020$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC53,650$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC45,952$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC44,894$0 M0.04%0.09%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust40,646$0 M0.03%<0.01%newMay 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company38,835$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP37,837$0 M0.03%<0.01%−69%Jul 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC37,797$0 M0.03%<0.01%+6.7%Jul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC25,983$0 M0.02%0.03%+31%Jun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC23,800$0 M0.02%<0.01%−6.7%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION18,600$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC16,453$0 M0.01%<0.01%+7.9%Jul 31, 2026
🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc.14,900$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP15,790$0 M0.01%<0.01%−80%Jul 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC13,825$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.12,778$0 M0.01%<0.01%+1.5%Jul 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.8,193$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC7,593$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Thrivent Moderate Allocation PortfolioThrivent Financial for Lutherans7,568$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC7,309$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Thrivent Moderately Aggressive Allocation PortfolioThrivent Financial for Lutherans7,223$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP6,246$0 M<0.01%<0.01%−29%Jul 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC5,119$0 M<0.01%<0.01%+8.6%May 31, 2026
🇺🇸 AZL DFA U.S. Core Equity FundAllianz Investment Management LLC5,379$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC4,268$0 M<0.01%<0.01%−5.3%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC4,044$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC4,003$0 M<0.01%<0.01%−41%May 31, 2026
🇺🇸 LVIP Dimensional U.S. Core Equity 1 FundLincoln Financial Investments Corporation3,581$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC3,093$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation2,609$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC2,547$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Thrivent Aggressive Allocation PortfolioThrivent Financial for Lutherans2,300$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC2,059$0 M<0.01%<0.01%−13%Jun 30, 2026
🇺🇸 Thrivent Moderately Conservative Allocation PortfolioThrivent Financial for Lutherans1,825$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 JNL/DFA U.S. Core Equity FundJackson National Asset Management, LLC1,541$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Thrivent Global Stock PortfolioThrivent Financial for Lutherans1,440$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC575$0 M<0.01%<0.01%+6.7%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 62 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Fate Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$336 K
7 sales, 3 insiders
Net, 12 months
-$336 K
open market only
Insiders on file
33
since
$669 K-$574 K$0Nov 2023: bought $0 (0 trades), sold $58 K (1 trades)Nov 23Dec 2023: bought $166 K (1 trades), sold $6 K (1 trades)Jan 2024: bought $0 (0 trades), sold $219 K (6 trades)Jan 24Mar 2024: bought $0 (0 trades), sold $19 K (1 trades)Aug 2024: bought $0 (0 trades), sold $3 K (1 trades)AugDec 2024: bought $669 K (1 trades), sold $574 K (1 trades)Jan 2025: bought $0 (0 trades), sold $31 K (3 trades)Jan 25Aug 2025: bought $0 (0 trades), sold $25 K (2 trades)Jan 2026: bought $0 (0 trades), sold $17 K (2 trades)Jan 26May 2026: bought $0 (0 trades), sold $103 K (2 trades)Aug 2026: bought $0 (0 trades), sold $204 K (2 trades)AugNov 2026: bought $0 (0 trades), sold $14 K (1 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Fate Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Kamal AdawiChief Financial OfficerSell-6,582$2.055$14 K93,418Form 4
filed Bahram ValamehrPresident and CEO, DirectorSell-43,947$2.460$108 K591,815Form 4
filed Cindy TahlSee RemarksSell-38,800$2.460$95 K589,355Form 4
filed Cindy TahlSee RemarksSell-25,590$1.880$48 K628,155Form 4
filed Bahram ValamehrPresident and CEO, DirectorSell-28,946$1.880$54 K635,762Form 4
filed Cindy TahlSee RemarksOption exercise+122,220$1.320$161 K609,301Form 4
filed Cindy TahlSee RemarksOption exercise+44,444$1.050$47 K653,745Form 4
filed Robert S. EpsteinDirectorOption exercise+25,000$1.690$42 K36,331Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Fate Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
10.0 M
8.6% of shares · 8.32 days to cover
Buybacks, Q1 2014
$0M
Q1 2014
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-6.49 reverse split

Fate Therapeutics, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q1 2014Q1 2014$0M

Trading halts

  • 2024-11-18 14:35 UTC, code LUDP, resumed 14:40 UTC

Fails to deliver

  • : 475 shares at $2.17
  • : 1,012 shares at $2.07
  • : 220 shares at $1.79
  • : 1,977 shares at $2.15
  • : 4,007 shares at $2.37

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Fate Therapeutics, Inc. scorecard#

Passes 3 of the 18 checks that could be worked out: strongest in financial health (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.3×Price to book 1.3× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median39.7×Price to sales 39.7× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-42.5%Free cash flow is -42.5% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 6
    • ✗Revenue grew in the newest year-51.2%Revenue down 51.2% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-59.0%-59.0% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-59.0%-59.0% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-1.15 vs -1.64Diluted EPS -1.15 in fiscal 2025 against -1.64 the year before (report's currency).
    • ✓Net income higher than five years earlier-$136 M-$136 M in fiscal 2025 against -$173 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$136 MNet income -$136 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-51.8%-51.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities5.8×Current ratio 5.79 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-6.18Z-score -6.18 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year4.5%Diluted shares up 4.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Fate Therapeutics, Inc.'s statements, beside the median of Biotechnology.

Fate Therapeutics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Return on equity-51.8%-61.0%
Revenue growth, 3 years a year-59.0%12.9%
Revenue growth-51.2%15.8%

1of 7on the Piotroski tests of financial strength

  • Revenue fell 51.2% against the year before.
  • Net loss of $136 million, the 15th loss-making year in a row.
  • Free cash flow was negative: -$112 million.

Fate Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Fate Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue6.61464965631114.74.14.4
Research and development10813517332021612688563426
General and administrative4774818457342416129.9
Operating expenses154224254405273160111724636
Operating income−148−210−191−308−217−128−101−67−42−32
Interest and finance income1117175.81.32.44.32.20.60.1
Interest expense and finance costs————001.81.71.31.6
Other non-operating income (expense)112430274.8−452.60.5−0.8−1.5
Income tax0.0000000———
Net income including minority interests−136−186−161−282−212−173−98−67−43−33
Net income attributable to shareholders−136−186−161−282−212−173−98−67−43−33
Earnings per share, basic-1.15-1.64-1.64-2.91-2.24-2.10-1.44-1.19-1.02-1.05
Earnings per share, diluted-1.15-1.64-1.64-2.91-2.24-2.10-1.44-1.19-1.02-1.05
Shares, weighted average (basic)11911498979582————
Shares, weighted average (diluted)1191149897958268564232
Balance sheet
Cash and cash equivalents473642611341671001918989r
Short-term investments157243273375482————3.5
Receivables0.93.51.8388.75.5—0.5——
Other current assets4.19.315278.85.95.73.71.61.2
Current assets20929233250263349422720510393
Property, plant and equipment5764971109232115.12.61.6
Right-of-use (leased) assets42476266716723———
Long-term investments1.5281.04.9101—39———
Total assets31944150670692162230221310595
Accounts payable2.79.44.78.38.66.35.84.21.70.9
Debt due within a year———————2.4—8.2
Current liabilities363939114818628271115
Long-term debt———————12152.5
Lease liabilities (non-current)7378971041099425———
Retained earnings−1,534−1,398−1,212−1,051−769−557−384−285−219−176
Shareholders' equity2073193684846793842451607773
Total liabilities and equity31944150670692162230221310595
Shares outstanding1151149997968876655341
Cash-flow statement
Depreciation and amortization131918145.93.12.21.21.00.9
Share-based compensation254143795431176.33.63.2
Cash from operating activities−106−123−132−248−163−39−83−39−37r−30
Capital expenditure−6.0−0.7−6.2−36−51−4.9−7.4−2.3−1.7−0.5
Cash from investing activities11112113167−324−161−157−0.5−10−4.1
Debt issued————————15—
Debt repaid——————−15—−11−7.7
Shares issued————41218916213543—
Cash from financing activities5.51000.19.245328315014147r58
Change in cash11−11−20−72−3483−911020.324
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Fate Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.2 M
Bahram Valamehr
Other top executives, average
$913 K
the CEO earned 2.5× this
$100 invested is now
$10
Fate Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Bahram Valamehr$2.2 M$1.6 M$913 K$10
2024J. Scott Wolchko$4.2 M$1.6 M$3.5 M$16
2023J. Scott Wolchko$3.5 M−$360 K$2.9 M$37

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Fate Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Restructuring 1 · Directors and officers 9 · Material agreement 2 · Agreement ended 1 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 11

Fate Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreementAgreement ended8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
RestructuringResults announced8-K
Shareholder vote8-K/A
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officersMaterial agreement8-K
Results announced8-K
Directors and officers8-K
Bylaws or fiscal year changed8-K
Directors and officersShareholder vote8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Fate Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2020$50 MPrivate placement after listing$50 to $250 million1equitySEC
Apr 2020$50 MPrivate placement after listing$50 to $250 million1equitySEC
Nov 2016$57 MPrivate placement after listing$50 to $250 million21equitySEC
Aug 2016$10 MPrivate placement after listing$10 to $50 million4equitySEC
May 2015$8 MPrivate placement after listing$2 to $10 million1equitySEC
May 2012$9 MNo. 2$2 to $10 million17equitySEC
Nov 2009$36 MNo. 1$10 to $50 million18equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Fate Therapeutics, Inc.#

2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $122 K a year.

Certified, FY2026
2
#1,533 among companies on value.today
Worker positions
2
Median wage offered
$122 K
a year, full-time
Applications filed
2
Fate Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Associate Scientist, In Vivo PharmacologyMolecular and Cellular Biologists2$122 K

Where: San Diego, CA 2

Fate Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202622$122 K2
FY202533$125 K3
FY202422$130 K2
FY20231010$107 K11
FY202266$108 K7
FY202177$95 K7
FY202066$83 K6

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Fate Therapeutics, Inc.

Layoffs at Fate Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
315
2023–2025
Latest
—
2025-08-07
Fate Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025············—
2023315···········315
Fate Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
12% of workforceRestructuring planSEC 8-K“In connection with the Restructuring, the Company committed to a reduction in total workforce by approximately 12% (the “RIF”).”Filing
effective 217 peopleLayoffWARN noticeSan Diego, CaliforniaNotice list
effective 43 peopleLayoffWARN noticeSan Diego, CaliforniaNotice list
effective 34 peopleLayoffWARN noticeSan Diego, CaliforniaNotice list
effective 21 peopleLayoffWARN noticeSouth San Francisco, CaliforniaNotice list
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Fate Therapeutics, Inc. compares in Biotechnology

  • Market cap$264 M · higher than 49% of 726
  • Revenue$7 M · higher than 38% of 647
  • Revenue growth-51.2% · higher than 17% of 438
  • Price / sales39.7× · lower than 21% of 339
  • Price / book1.3× · lower than 73% of 534
  • FCF yield-42.5% · higher than 27% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Fate Therapeutics, Inc.🇺🇸$264 M——-51.2%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Fate Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Fate Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Fate Therapeutics, Inc.? Suggest a correction